MatthewHelmutKulkeMD

Oncology • Boston, MA

Chief, Section of Hematology and Medical Oncology, Boston University and Boston Medical Center

Join to view full profile

Dr. Kulke is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kulke's full profile

Already have an account?

Office
820 Harrison Street
Boston Medical Center
Boston, MA 02118
Phone+1 617-638-7012

Summary

Matthew H. Kulke, MD is the Chief of Hematology/Oncology at Boston Medical Center, Co-Director of the BU/BMC Cancer Center and the Zoltan Kohn Professor at Boston University Chobanian & Avedisian School of Medicine (Boston University Chobanian & Avedisian School of Medicine). He is internationally recognized for his expertise in neuroendocrine tumors and has led numerous national and international clinical trials resulting in new drugs and therapies for this indication. He is a past chair of the NCCN neuroendocrine tumor guidelines committee and the North American Neuroendocrine Tumor Society. Dr. Kulke has published more than 200 peer-reviewed articles in his area of expertise.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1997
Brigham and Women's HospitalResidency, Internal Medicine, 1992 - 1995
University of California San Francisco School of MedicineClass of 1992
Princeton UniversityBA, Molecular Biology, Summa Cum Laude, 1983 - 1987

Certifications & Licensure

MA State Medical License 1995 - 2026

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Super Doctor SuperDoctors.com

Clinical Trials

Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas Start of enrollment: 2001 Jan 01
Completed
Phase 2
Tarceva and Capecitabine for Pancreatic Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 2
Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer Start of enrollment: 2004 Oct 01
Completed
Phase 2
Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors Start of enrollment: 2004 Nov 01
Completed
Phase 2
Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus Start of enrollment: 1998 Aug 01
Completed
Phase 2
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors Start of enrollment: 2002 May 01
Completed
Phase 2
Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma Start of enrollment: 2000 Jun 01
Completed
Phase 2
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors Start of enrollment: 2006 May 01
Completed
Phase 2
Pemetrexed in Patients With Advanced Neuroendocrine Tumors Start of enrollment: 2005 Dec 01
Completed
Phase 2
A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer Start of enrollment: 2007 Nov 01
Unknown status
Phase 1
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
Active, not recruiting
Phase 3
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Start of enrollment: 2010 Mar 01
Completed
Phase 2
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Start of enrollment: 2010 Oct 15
Completed
Phase 2
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Start of enrollment: 2012 Jul 01
Completed
Phase 2
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Start of enrollment: 2012 Sep 06
Completed
Phase 3
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2014 Oct 01
Withdrawn
Phase 2
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Start of enrollment: 2016 Dec 08
Completed
Phase 1, Phase 2
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors Start of enrollment: 2018 Nov 01
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

241 citations
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Antonino Glaviano, Aaron S C Foo, Hiu Y Lam, Kenneth C H Yap, William Jacot
Molecular Cancer. 2023-08-18
78 citations
Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors
Zhi Rong Qian, Tingting Li, Monica Ter-Minassian, Juhong Yang, Jennifer A. Chan
Pancreas. 2016-11-01
154 citations
Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer.
Alison P. Klein, Brian M. Wolpin, Harvey A. Risch, Rachael Z. Stolzenberg-Solomon, Evelina Mocci
Nature Communications. 2018-02-08

Press Mentions

TerSera® Announces Publication of Real-World Study on Xermelo® (Telotristat Ethyl) in Patients with Carcinoid Syndrome DiarrheaOctober 27th, 2021
Boston Medical Center, Dana-Farber Cancer Institute, Massachusetts General Hospital Formalize Cancer Clinical Trial CollaborationSeptember 29th, 2020
Gerald Denis Named Shipley Prostate Cancer Research ProfessorAugust 20th, 2020
Join now to see all

Grant Support

Molecular And Genetic Analysis Of Neuroendocrine Tumor Risk And SurvivalNational Cancer Institute2011
Molecular Analysis Of Esophageal Cancer SurvivalNational Cancer Institute2003–2007